Serum Obestatin Levels Research Articles

Serum Obestatin Levels in PCOS and its Relation with Homa-IR

Background: Is to investigate the level of Obestatin in PCOS patients and compare with controls and also see the correlations between the serum Obestatin levels and HOMA-IR.
 Patients and methods: We analyzed 30 patients with PCOS and 20 normal women as controls. PCOS patients were divided into two groups based on obese group and non-obese group Serum Obestatin levels, Insulin Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) determined and compared among both groups.
 Results: Serum Obestatin levels were significantly lower in obese PCOS group than non-obese and control.

Does Obestatin Level Change in Endometrial Pathologies? A Case-Control Study in A Tertiary Care Hospital

Background: The rising incidence of endometrial cancer has been associated with increases in obesity and physical inactivity. We investigated the clinical significance of serum obestatin levels in women with endometrial cancer, endometrial hyperplasia, and age-matched healthy controls. 
 Material and Methods: The present study was a case-control study conducted at a single center between May 2014 and July 2015. The medical records of 90 patients with a final histopathologic diagnosis after therapeutic curettage for abnormal uterine bleeding were reviewed and categorized by diagnosis. The study population included women with adenocarcinoma of the endometrium (n= 33), hyperplasia of the endometrium (n= 27), and proliferative endometrium (n=30) according to histopathological diagnosis. The women with proliferative endometrium formed the control group.
 Results: Endometrial cancer was diagnosed in 33 (36.6%) of the patients who presented to our clinic for abnormal uterine bleeding. In the group with endometrial cancer, the mean age was 55.2 ± 8.6 years. There were no differences in obestatin levels between groups (p > 0.05). In the ROC curve analysis, the area under the curve value was 0.574, and obestatin did not prove to be a significant marker for cancer prediction in the population involved in the study.
 Conclusion: This study did not demonstrate a clear association between circulating levels of obestatin and endometrial pathologies.

Diagnostic value of serum levels of galanin and obestatin in patients with gastric cancer

SUMMARYOBJECTIVE:Gastric cancer ranks the third among the cancer-related deaths. It is diagnosed at advanced stage in many patients due to malignant proliferation and has a poor prognosis. Currently, no instrument or biomarker has been proven to diagnose the disease before the advanced stages. This study aimed to measure the serum levels of galanin and obestatin, which were examined in various studies including cancer studies, and to discuss their diagnostic value in gastric cancers.METHODS:In this study, 30 adult patients with gastric cancer and 30 healthy adults in the control group were examined prospectively. The demographic characteristics and serum levels of galanin and obestatin in the patient and control groups were recorded.RESULTS:The mean serum level of galanin in the patient and control groups was 19.73±5.04 and 35.59±10.94 pg/mL, respectively. The mean serum level of obestatin in the patient and control groups was 40.21±5.82 and 15.15±3.32 ng/mL, respectively. A significant difference was found between the groups (p<0.001).CONCLUSION:Serum levels of galanin were lower and serum levels of obestatin were higher in patients with gastric cancer compared to the healthy individuals. Serum levels of obestatin and galanin can be used as potential biomarkers in the diagnosis of gastric cancer.

Investigation of the association between cardio-metabolic risk factors, neurotrophins and gastric hormones among apparently healthy women: A cross-sectional analysis.

Introduction: Although, some evidence has shown that obestatin, ghrelin, and neurotrophic factors can be involved in the development of cardio-metabolic risk factors, there are some contradictions in this regard. We aimed to investigate the association of serum neurotrophic factors and some gastric hormones with cardio-metabolic risk factors among apparently healthy women. Methods: In the present study, 90 apparently healthy women were recruited by a convenient sampling method from the nutrition counseling clinic in Tabriz, Iran. All participants need dietary counseling for weight loss and were recruited before receiving any dietary interventions. Anthropometric, biochemical, physical activity, and blood pressure (BP) measurements, as well as dietary assessment, were done in all participants. Results: Women who were in the highest tertile of serum obestatin levels (OR=0.118, 95% CI:0.035-0.396) had a significantly lower risk for development of hypertriglyceridemia compared to the reference group (Ptrend < 0.001). Participants in the highest tertile of serum ghrelin had a significant lower risk of hypertriglyceridemia, hyperglycemia, low HDL-C, and MetS (Ptrend < 0.05). Women who were in the higher tertile of serum NGF levels had a significantly lower risk for development of hypertriglyceridemia after adjustment for potential confounding variables (OR=0.091, 95% CI: 0.023-0.361 and OR=0.193, 95% CI: 0.057-0.649 respectively). Conclusion: In the current study serum levels of obestatin, NGF, and ghrelin were associated with some cardio-metabolic risk factors such as hypertriglyceridemia and MetS. It seems that these factors are associated with metabolic regulation. However, further studies are needed to substantiate this claim.

The association of a body shape index and visceral adiposity index with neurotrophic, hormonal and metabolic factors among apparently healthy women: a cross-sectional analysis.

A body shape index (ABSI) and visceral; adiposity index (VAI) can reflect some cardio-metabolic risk factors in the population. To the best of our knowledge, there are no previous studies conducted on the assessment of the association between neurotrophic factors, Ghrelin and Obestatin with ABSI and VAI. We aimed to investigate this association among apparently healthy women. Ninety apparently healthy women were recruited in the present study. All participants were in need of dietary intervention for weight loss and participated in the study before receiving any intervention. Dietary, anthropometric, physical activity, stress level and biochemical assessments, as well as blood pressure measurements were done for all participants. Women in the highest tertile of ABSI had significantly lower SBP compared to the lowest ABSI tertile. Women who were in the highest tertile of VAI had significantly lower serum Obestatin levels compared to the first and second tertiles in both crude and adjusted comparisons. Serum NGF, Obestatin and Ghrelin levels were significantly lower in the highest tertile of VAI compared to the lowest tertile in both crude and adjusted comparisons. HOMA-IR, serum insulin, LDL-C, TG and TC were significantly higher in the highest tertile of VAI compared to the lowest tertile. QUICKI in the highest tertiles were significantly lower than the first tertile in adjusted model. This evidence can be useful for researchers in applying appropriate anthropometric indices regarding different populations with multifactorial metabolic complications. The current findings need approving by prospective population study and also clinical trial researches.

Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome.

ObjectiveIn this study we aimed to assess anorexigenic peptide levels in patients with or without polycystic ovary syndrome (PCOS) and their effects on assisted reproductive treatment (ART) outcomes.MethodsA prospective case-control study was conducted in a tertiary care university-based ART clinic. Eighty-three patients were included in the study. The PCOS group included 41 patients, and the non-PCOS group included 42 controls. The 2003 Rotterdam criteria were used for PCOS patient selection. The ART indications in the non-PCOS group were tubal factor or unexplained infertility. Venous blood samples were taken on the third day of the menstrual cycle to determine the serum anorexigenic peptide levels. The enzyme-linked immunosorbent assay method was used for laboratory analyses.ResultsIn the PCOS group, serum obestatin levels were significantly lower than in the control group, but serum anorexigenic peptide levels were similar in PCOS patients with or without clinical pregnancy. Ovarian hyperstimulation syndrome (OHSS) was diagnosed only in PCOS patients, and the obestatin levels of OHSS patients were significantly lower than those of other PCOS patients.ConclusionsBaseline anorexigenic peptide levels did not affect the clinical pregnancy rate in ART cycles. Obestatin may play a role in the pathophysiology of OHSS. This possibility should be confirmed in further research.

Study of serum obestatin level in type 2 diabetic patients with diabetic kidney disease

Objective The aim was to evaluate serum obestatin level in type 2 diabetic patients with diabetic kidney disease as a diagnostic and a prognostic marker. Background Obestatin has been reported to have important effects on endothelial cells as decreasing vascular cell adhesion molecule-1 expression and increasing oxidized low-density lipoprotein binding to the macrophage. Participant and methods A cross-sectional study was carried out on 100 patients sin the Department of Internal Medicine, Menoufia University Hospitals. A total of 100 patients was divided into different groups. Group I: 25 type 2 diabetic patients with normoalbuminuric; group II: 25 type 2 diabetic patients with microalbuminuria; group III: 25 type 2 diabetic patients with macroalbuminuria; and group IV: 25 healthy individuals as a control group. All participants were subjected to history taking, complete physical examination, anthropometric measurement, waist circumferences, fasting blood glucose, 2h-postprandial blood glucose, glycated hemoglobin, kidney function tests, estimated glomerular filtration rate, urine analysis, abdominal ultrasound, liver profile, lipid profile, complete blood count, and serum obestatin level by ELIZA kit. Results Obestatin was 2.9 ± 0.4 ng/dl in group I, 3.7 ± 0.7 g/dl in group II, 5.5 ± 0.9 g/dl in group III, and 2.4 ± 0.6 g/dl in group VI. These results were significantly higher in group III than in groups I, II, and VI (P Conclusion Higher serum levels of obestatin were associated with macroalbuminuria, suggesting that obestatin may have a role in the underlying pathogenic mechanisms that lead to diabetic kidney disease.

Alterations of Obestatin, Cardiac Markers and Lipid Profile Levels in Type 2 Diabetes Mellitus

The current investigation aimed to test the alterations of the levels of obestatin hormone, lipid profile and cardiac function markers in relation to hyperglycemia in patients with non-insulin diabetes mellitus. The study included 118 diabetic subjects (56 males, 62 females) and 60 healthy non-diabetic subjects (30 males, 30 females). Diabetic and healthy subjects were age-matched. Serum levels of obestatin, lipid profile markers including total cholesterol (STC), triglycerides (STG), low and high density lipoproteins (LDL-C and HDL-C), as well as cardiac function markers including, creatine kinase and lactate dehydrogenase enzymes were determined in all subjects. The findings revealed a remarkable decrease in the level of serum obestatin in both diabetic males and females with both age ranges (40-59 and 60-80 years). On the other hand, the results showed that serum STC, LDL-C, and STG levels were statistically significantly elevated, while that for HDL-C was significantly decreased in diabetic males and females with both age ranges. Concerning the cardiac markers, the results found out that the levels of CK-MB and LDH were significantly increased in type 2 diabetic males and females with both age ranges. The results suggested that a low concentration of obestatin is a significant risk factor for type 2 DM, with a key role for this hormone in the pathogenesis. Accordingly, altered levels of obestatin could be used as an important indicator for type 2 DM. The current study also suggests a direct relationship between lipid profiles, except for HDL, the decreased obestatin level, the increased cardiac function markers, and hyperglycemic status in type 2 DM.

39 Concentration of obestatin in different stages of ovarian activity in cattle

The objective of the present study was to measure serum levels of obestatin by ELISA with the purpose of establishing parameters and being able to use it as an endocrine marker for the selection of reproductive characteristics of milk and beef cattle. In test 1, 15 Creole cows with genetic tendencies of Charolais, Angus, Brangus, and Gelbvieh were sampled in diestrus and 15 in proestrus, determining their structures with an Aloka Prosound ultrasound with a 7.5-MHz linear transducer. In test 2, 16 Holstein cows were sampled in 2 different ovarian stages, diestrus and proestrus. The standardized technique was a bovine obestatin 96-well ELISA kit from My Biosource Inc. The data were analysed by measuring central tendency and linear regression, where the average levels of obestatin were related to the corpus luteum size and size and number of follicles in milk and beef cattle. We found average levels of 556.99 and 453.35 pg for beef and dairy cattle, respectively (P&amp;lt;0.05). We also found a significant difference (P&amp;lt;0.05) in obestatin concentrations depending on the size of the follicles (751.74, 615.33, and 357.39 pg for follicles of 15, 10, and 5mm, respectively). We found a significant difference in concentration of obestatin (644.53, 550.69, and 455.88 pg; P&amp;lt;0.05) for corpus luteum sizes of &amp;gt;20mm, 10–20mm, and &amp;lt;10mm, respectively. In dairy cattle, obestatin levels were also evaluated at different stages of the cycle, and we found concentrations of 414.79 pg in diestrus and 530.48 pg in proestrus (P&amp;lt;0.05). We conclude that obestatin concentration is positively associated with a greater number and size of follicles as well as with larger corpus luteum because its effect on cell proliferation interacting positively with high levels of progesterone in the blood. We found higher concentrations in beef cattle than in dairy cattle.

Copeptin and Obestatin Levels in Polycystic Ovary women and their Relation to Obesity, insulin metabolism and Cardiovascular diseases

Objective: is to investigate the correlations between the serum levels of copeptin and obestatin, carotid artery intima-media thickness (CIMT), and brachial artery flow mediated dilatation (FMD) in obese and non-obese women with PCOS. Design: Prospective randomized study. Setting: Obstetrics and Gynecology Department, El-Hussein and Sayed Galal University Hospitals, Al-Azhar University. Patient(s): We analyzed 54 patients with PCOS and 20 normal women as controls. PCOS patients were divided into two groups based on body mass index (BMI): obese group (BMI > 30 kg/m2, n = 28) and non-obese group (BMI < 30 kg/m2, n = 26). Serum Copeptin and Obestatin levels, Insulin Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), CIMT and brachial artery FMD were determined and compared among both groups. Result(s): Serum Obestatin levels were significantly lower in obese PCOS group than non-obese and control. While Serum Copeptin levels were significantly higher in obese PCOS group than non-obese and control. Brachial artery FMD was lower in the PCOS groups than control. Obestatin was positively correlated with cardiovascular risk factor (FMD), whereas Copeptin was negatively correlated with FMD Conclusion(s): Obestatin and Copeptin may provide useful information regarding future cardiovascular risk in PCOS patients as Obestatin was negatively correlated and Copeptin was positively correlated with cardiovascular risk factor (FMD). Keywords: Cardiovascular diseases, Copeptin, Insulin resistance, Obesity, Obestatin, Polycystic ovary

Unacylated ghrelin is correlated with the decline of bone mineral density after Roux-en-Y gastric bypass in obese Chinese with type 2 diabetes

BackgroundBariatric surgery is an effective and therapeutic way for different metabolic diseases. It has become a focus of attention about the effects and molecular mechanisms to bone metabolism. ObjectiveWe aim to assess the changes of bone mineral density (BMD) among Chinese obese individuals with type 2 diabetes who have undergone Roux-en-Y gastric bypass surgery (RYGB). Two ghrelin gene products, namely unacylated ghrelin (UAG) and obestatin, were evaluated the roles in this pathologic process. SettingUniversity-affiliated hospital, China. MethodsThirty patients who had received RYGB were enrolled in the study. Changes in anthropometric parameters, metabolic indexes, and serum UAG and obestatin were assessed preoperatively, 6, 12, and 24 months postoperatively. BMD at lumbar spine (LS), femoral neck (FN), and total hip (TH) were identified. ResultsRYGB resulted in statistical reductions of BMD in 3 different skeletal parts. After the first 6 months, BMD began to reduce and maintained a declining trend until 24 months postoperatively. Comparing to baseline, the maximal reduction of BMD was as high as 10.28% in total hip. The plasma concentration of UAG increased after 6 months (51.61 ± 55.21 versus 71.95 ± 64.91 pg/mL; P < .01), as well as the serum obestatin level (1.65 ± 0.88 versus 1.71 ± 0.99 ng/mL; P > .05). Although there was a slight drop of both peptides in the first year, they were still above the baseline. Notably, in the second year, UAG and obestatin rose to their peak values, respectively (91.90 ± 77.11 pg/mL and 1.74 ± 1.09 ng/mL). There was a negative correlation between UAG and BMD in all sites. Multiple linear regression analysis showed that the UAG level was the independent parameter associated with BMD at baseline (FN: β = -.407, P = .012 and TH: β = -0.396, P = .030 respectively), as well as the changes of UAG that were independently related with reduction percentage of LS BMD after 24 months (β = - .379, P = .046). ConclusionThe reduction of BMD in obese Chinese with type 2 diabetes was observed after RYGB. The pronounced increase of serum UAG acts as an independent risk factor for the decrease of BMD.

Evaluation of Serum Obestatin Level in Rat Model of Diabetic Nephropathy

Evaluation of Serum Obestatin Level in Rat Model of Diabetic Nephropathy

Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients

BackgroundObestatin is a ghrelin-associated peptide, derived from preproghrelin. Although many of its effects are unclear, accumulating evidence supports positive actions on both metabolism and cardiovascular function. To date, level of obestatin and its correlations to the lipid subfractions in non-diabetic obese (NDO) patients have not been investigated.MethodsFifty NDO patients (BMI: 41.96 ± 8.6 kg/m2) and thirty-two normal-weight, age- and gender-matched healthy controls (BMI: 24.16 ± 3.3 kg/m2) were enrolled into our study. Obestatin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions, intermediate density lipoprotein (IDL) and very low-density lipoprotein (VLDL) levels and mean LDL size were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint).ResultsSerum level of obestatin was significantly lower in NDO patients compared to controls (3.01 ± 0.5 vs. 3.29 ± 0.6 μg/ml, p < 0.05). We found significant negative correlations between the level of obestatin and BMI (r = − 0.33; p < 0.001), level of serum glucose (r = − 0.27, p < 0.05), HbA1c (r = − 0.38; p < 0.001) and insulin (r = − 0.34; p < 0.05). Significant positive correlation was found between obestatin level and the levels of ApoA1 (r = 0.25; p < 0.05), large HDL subfraction ratio and level (r = 0.23; p < 0.05 and r = 0.24; p < 0.05), IDL (r = 0.25 p < 0.05) and mean LDL size (r = 0.25; p < 0.05). Serum VLDL ratio and level negatively correlated with obestatin (r = − 0.32; p < 0.01 and r = − 0.21; p = 0.05). In multiple regression analysis obestatin was predicted only by VLDL level.ConclusionsBased on our data, measurement of obestatin level in obesity may contribute to understand the interplay between gastrointestinal hormone secretion and metabolic alterations in obesity.

Serum levels of spexin and kisspeptin negatively correlate with obesity and insulin resistance in women.

Spexin (SPX) and kisspeptin (KISS) are novel peptides relevant in the context of regulation of metabolism, food intake, puberty and reproduction. Here, we studied changes of serum SPX and KISS levels in female non-obese volunteers (BMI<25 kg/m(2)) and obese patients (BMI>35 kg/m(2)). Correlations between SPX or KISS with BMI, McAuley index, QUICKI, HOMA IR, serum levels of insulin, glucagon, leptin, adiponectin, orexin-A, obestatin, ghrelin and GLP-1 were assessed. Obese patients had lower SPX and KISS levels as compared to non-obese volunteers (SPX: 4.48+/-0.19 ng/ml vs. 6.63+/-0.29 ng/ml; p<0.001, KISS: 1.357+/-0.15 nmol/l vs. 2.165+/-0.174 nmol/l; p<0.01). SPX negatively correlated with BMI, HOMA-IR, insulin, glucagon, active ghrelin and leptin. Positive correlations were found between SPX and QUICKI index, McAuley index, serum levels of obestatin, GLP-1 and adiponectin and orexin-A Serum KISS negatively correlated with BMI, HOMA-IR, serum levels of insulin, glucagon, active ghrelin and leptin. KISS positively correlated with QUICKI index, McAuley index and adiponectin. In summary, SPX and KISS show negative correlations with obesity, insulin resistance indices, and hormones known to affect insulin sensitivity in females. Both, SPX and KISS could be therefore relevant in the pathophysiology of obesity and insulin resistance.

Age modifies the association between serum obestatin, appetite and nutritional status in maintenance hemodialysis patients.

Increased age is strongly associated with anorexia and protein-energy wasting (PEW) in maintenance hemodialysis (MHD) population. We hypothesized that the association of obestatin, a recently discovered anorexigenic gut hormone, with appetite and nutritional status differs by age groups. We performed a cross-sectional study on 261MHD patients. Obestatin, acyl-ghrelin, markers of inflammation (CRP, IL-6, TNF-α) and nutrition (self-reported appetite, dietary intake, biochemical nutritional parameters, and body composition) were measured. Obestatin was associated with appetite in multivariate analyses even after controlling for such confounders as lean body mass (LBM), IL-6 and acyl-ghrelin in patients younger than 71 years. For each ng/ml increase in obestatin levels, the odds for diminished appetite was 0.75 (95% CI: 0.59-0.96). However, these associations were not observed in patients 71 years and older. Multivariable logistic regression models (including appetite) also showed increasing odds for PEW (defined by ESPEN consensus-based criteria for the diagnosis of malnutrition) across increasing serum obestatin levels (OR: 1.51, 95% CI: 1.05-2.18) in patients 71 years and older. However, after lean body mass (LBM) was added to this model, the association between obestatin and malnutrition was abolished (OR: 1.26, 95% CI: 0.83-1.91). The association between serum obestatin, appetite and PEW differs depending on age in MHD patients. A positive link with appetite exists in patients younger than 71 years, whereas this relationship disappears by the age of 71. In older MHD patients, obestatin is associated with PEW through mechanisms related to LBM, but not to appetite.

Serum ghrelin, but not obestatin, is a potential predictor of acute pancreatitis severity.

The roles of ghrelin and obestatin in AP remain controversial.This study investigates the effects and the predictive value of serum ghrelin and obestatin levels in the early stage of AP.A total of 193 consecutive patients with AP and 24 healthy controls were included. Patients were divided into mild acute pancreatitis (MAP), moderately severe acute pancreatitis (MSAP), and severe acute pancreatitis (SAP) groups. Serum levels of ghrelin and obestatin were measured on the first, third, and fifth days of hospitalization. The predictive value of serum ghrelin and obestatin levels on the first day in AP was examined using receiver-operating characteristic (ROC) curves.On the first day of hospitalization, the mean serum ghrelin level was significantly lower in patients with AP than in controls (P < .01). The serum ghrelin concentration decreased with increasing AP severity and was lower in patients with SAP than in those with MAP and MSAP (P < .05). It increased gradually from the first to the fifth day after treatment. ROC curves demonstrated that the serum ghrelin level on the first day had some predictive value for AP severity (area under the ROC curve = 0.646), with an optimal cut-off value of 87.83 pg/mL. Logistic regression showed that the serum ghrelin level had independent predictive value for non-MAP (odds ratio = 10.94; 95% confidence interval, 5.08–23.55; P < .01). The serum obestatin level did not differ significantly between patients with AP and controls and had the limited predictive value for non-MAP (area under the ROC curve = 0.564). However, the serum obestatin concentration showed a “warning” effect regarding AP etiology; on the first day of treatment, it was significantly lower in patients with AP of hypertriglyceridemic etiology than in those with AP of biliary, alcohol-related, and other etiologies (P = .05, P = .031, and P = .029, respectively).Serum ghrelin and obestatin levels may be related to the progression of AP in the early stage. Only the serum ghrelin level is a potential predictor of AP severity in the early stage. Obestatin may be involved in the pathogenesis of AP caused by hypertriglyceridemia.

Alteration of ghrelin/obestatin ratio in adolescence with polycystic ovarian syndrome

Ghrelin, an endoggenous for the growth hormone secretagogue receptor, has been shown to participate in the regulation of energy homeostasis and pituitary hormone secretion. Obestatin, encoded by the same gene as ghrelin, is described as a physiological opponent of ghrelin. Ghrelin and obestatin are altered in polycystic ovary syndrome (PCOS), which is characterized by insulin resistance and pituitary hormone secretion disorder. The aim of this study was to evaluate ghrelin/obestatin imbalance in relation to insulin resistance and pituitary hormone in adolescence with PCOS. This restrospective case–control study included 33 adolescence with PCOS and 38 control adolescence. Ghrelin and obestatin concentrations in serum were determined by RIA, and the serum fasting glucose and Insulin were determined by the glucose oxidase color method and INS-EASIA. The serum LH and FSH were measured by highly specific hemiluminescence immunoassays. We found that the serum ghrelin levels and ghrelin/obestatin ratio were significant lower in PCOS group than in control group, and the serum obestatin levels were significant higher in PCOS group than in control group. The ghrelin/obestatin ratios were negatively correlation with LH/FSH ratio and insulin resistant index in PCOS group. The findings of this study suggest that ghrelin/obestatin imbalance may play a role in pathogenesis of adolescent PCOS.

Serum obestatin and omentin levels in patients with diabetic nephropathy.

Diabetic nephropathy is the leading cause of chronic kidney disease and accounts for almost 45% of all new patients requiring renal replacement therapy. Omentin and obestatin, two novel proteins were suggested to be associated with insulin resistance, type 2 diabetes and cardiovascular risk factors. Thus, we postulated that they may also have an association with diabetic nephropathy which is known to be an independent cardiovascular risk factor. In order to investigate such an association we compared serum omentin and obestatin levels in type 2 diabetic patients with normoalbuminuria (NA) and macroalbuminuria (MA). A total of 81 type 2 diabetic patients were separated into two groups according to their proteinuria status; patients with NA (n = 39) and patients with MA (n = 42). Two groups were compared in terms of serum omentin and obestatin levels. While s erum omentin levels did not differ among two groups (P = 0.407), serum obestatin levels were significantly higher in MA group (P = 0.001). The results of this study showed that higher serum levels of obestatin were associated with macro albuminuria suggesting that obestatin may have a role in underlying pathogenic mechanisms that leads to diabetic nephropathy.

Correlation analysis of serum obestatin expression with insulin resistance in childhood obesity.

Childhood obesity is a serious public health concern condition, as excess body fat can negatively affect a child's health. Obestatin is a hormone that regulates body weight by suppressing appetite and reducing food intake; fasting obestatin level is negatively correlated with basal insulin level. This study aims to investigate the role of obestatin in insulin resistance. A total of 54 children with simple obesity and 57 healthy controls were recruited. Levels of serum insulin, fasting blood glucose, cholesterol, triglyceride, low-density lipoprotein, and high-density lipoprotein were measured. Serum obestatin level was determined using an enzyme-linked immunosorbent assay. We found that body mass index and waist-hip ratio of obese children were significantly higher, while obestatin level in the obese group was significantly lower (P < 0.001), as compared to those of controls. In addition, obese children exhibited higher levels of insulin, total cholesterol, triglyceride, and low-density lipoprotein (P < 0.05) as compared to the controls. Fasting blood glucose and high-density lipoprotein levels were similar between the two groups (P > 0.05). Leptin level in the obese group was also higher (P < 0.05) as compared to that of control group. Results showed that insulin resistance index was positively correlated with body mass index, waist-hip ratio (r = 0.41, P < 0.001; r = 0.245, P < 0.001), and triglyceride level (r = 0.25, P = 0.04). Our study demonstrated that obestatin is negatively correlated with fasting insulin and leptin levels, and positively correlated with insulin resistance in obese children.

Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome

ObjectivePolycystic ovary syndrome (PCOS) is one of the most common endocrinopathies, affecting 5–8% of reproductive-age women. It is associated with insulin resistance, central obesity, type 2 diabetes mellitus, dyslipidemia, and cardiovascular diseases. The current study was undertaken to evaluate serum copeptin and obestatin levels, carotid artery intima-media thickness, and brachial artery flow mediated dilatation in obese and nonobese women with PCOS and age-matched healthy controls and to investigate their relationship with each other and with clinical, metabolic, and hormonal parameters and cardiovascular risk factors. MethodIn the study population, we analyzed 60 patients with PCOS and 30 age-matched healthy women as controls. The patients with PCOS were divided into two groups based on body mass index (BMI): obese group (BMI>30kg/m2, n=30) or nonobese group (BMI<30kg/m2, n=30). History was obtained and a physical examination, peripheral venous blood sampling, and carotid and brachial artery ultrasonography were performed. Serum copeptin and obestatin levels, total testosterone, C-reactive protein (CRP), glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, homeostasis model assessment for insulin resistance (HOMA-IR), carotid artery intima-media thickness (CIMT), and brachial artery flow-mediated vasodilation (FMD) were determined and compared among the groups. ResultsWomen with PCOS, especially obese ones, had higher triglycerides, HOMA-IR, total testosterone, CRP, systolic and diastolic blood pressure, and waist-to-hip ratio (WHR), and lower HDL. Serum obestatin levels were significantly lower in the obese PCOS group than they were in the nonobese and control groups (p<0.001). Serum copeptin levels were significantly higher in the obese PCOS group than they were in the nonobese PCOS and control groups (p<0.001). CIMT values were similar among the groups (p>0.05). Brachial artery FMD was lower in the PCOS groups than it was in the control group (p<0.001). Obestatin and FMD values were negatively correlated with cardiovascular risk factors, whereas copeptin was positively correlated. A significant positive correlation was found between copeptin, BMI, WHR, hirsutism score, total testosterone, and HOMA-IR. There was no correlation between CIMT, copeptin, obestatin, and FMD. A positive correlation was seen between CIMT, BMI, triglycerides, and HOMA-IR. ConclusionCopeptin and obestatin may provide useful information regarding future cardiovascular risk in PCOS patients as copeptin was positively correlated and obestatin was negatively correlated with cardiovascular risk factors.